Hopley CW - Search Results

1

Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.

Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS. Aquilante CL, et al. Among authors: hopley cw. J Clin Pharmacol. 2012 Nov;52(11):1725-38. doi: 10.1177/0091270011427907. Epub 2011 Dec 14. J Clin Pharmacol. 2012. PMID: 22174437 Clinical Trial.

2

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS. Aquilante CL, et al. Among authors: hopley cw. Br J Clin Pharmacol. 2013 Jan;75(1):217-26. doi: 10.1111/j.1365-2125.2012.04343.x. Br J Clin Pharmacol. 2013. PMID: 22625877 Free PMC article. Clinical Trial.

3

Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms.

Pacanowski MA, Hopley CW, Aquilante CL. Pacanowski MA, et al. Among authors: hopley cw. Expert Opin Drug Metab Toxicol. 2008 May;4(5):529-44. doi: 10.1517/17425255.4.5.529. Expert Opin Drug Metab Toxicol. 2008. PMID: 18484913 Review.

4

Evaluating the feasibility of a pharmacist-guided patient-driven intervention to improve blood pressure control in patients with CKD.

Hopley C, Andrews E, Klem P, Jonjak M, Grothe A, Ten Eyck P, You Z, Billups SJ, Lyon C, Kennelty K, Dixon B, Jalal D. Hopley C, et al. Pilot Feasibility Stud. 2019 Feb 12;5:23. doi: 10.1186/s40814-019-0410-0. eCollection 2019. Pilot Feasibility Stud. 2019. PMID: 30805198 Free PMC article.

5

Wound healing and functional outcomes after infrainguinal bypass with reversed saphenous vein for critical limb ischemia.

Chung J, Bartelson BB, Hiatt WR, Peyton BD, McLafferty RB, Hopley CW, Salter KD, Nehler MR. Chung J, et al. Among authors: hopley cw. J Vasc Surg. 2006 Jun;43(6):1183-90. doi: 10.1016/j.jvs.2005.12.068. J Vasc Surg. 2006. PMID: 16765235 Free article.

6

Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.

Hopley CW, Kavanagh S, Patel MR, Ostrom C, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Jones WS, Katona BG, Mahaffey KW, Norgren L, Rockhold FW, Hiatt WR. Hopley CW, et al. Vasc Med. 2019 Oct;24(5):422-430. doi: 10.1177/1358863X19864172. Epub 2019 Jul 24. Vasc Med. 2019. PMID: 31339474 Clinical Trial.

7

Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y₁₂ inhibitors: Insights from the EUCLID trial.

Hsia J, Kavanagh ST, Hopley CW, Baumgartner I, Berger JS, Fowkes GR, Jones WS, Mahaffey KW, Norgren L, Patel MR, Rockhold F, Blomster J, Katona BG, Hiatt WR, Bonaca MP. Hsia J, et al. Among authors: hopley cw. Vasc Med. 2021 Dec;26(6):608-612. doi: 10.1177/1358863X211017641. Epub 2021 Jun 3. Vasc Med. 2021. PMID: 34082620 Clinical Trial.

8

Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial.

Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Ostrom C, Patel MR, Jones WS, Hiatt WR. Fudim M, et al. Among authors: hopley cw. Circ Cardiovasc Qual Outcomes. 2020 Sep;13(9):e006512. doi: 10.1161/CIRCOUTCOMES.120.006512. Epub 2020 Aug 31. Circ Cardiovasc Qual Outcomes. 2020. PMID: 32862697

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page